Existing shareholders to receive the Company's legacy manufacturing business through a pro rata spin-off and a $2.0 million cash dividendHONG KONG, Nov. 5, 2026 /PRNewswire/ -- Highway Holdings Limited (NASDAQ:HIHO)
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity
ARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (NASDAQ:KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have signed a non-binding letter of intent (the
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory
ARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (NASDAQ:KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have finalized a definitive exclusive distribution and
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (NASDAQ:KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per
SUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (NASDAQ:ATER) ("Aterian" or the "Company"), a consumer products company, today announced separate transactions related to its previously announced
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA" or the "Company") today celebrated the landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026. The
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company at the forefront of artificial intelligence and cell and gene therapy innovation, today announced the
ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("Kala" or the "Company") today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON,
DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid
ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a
Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI systems directly within client environments where proprietary data never
